Skip to main content
Premium Trial:

Request an Annual Quote

DxS, Boehringer Ingelheim Partner on Companion Dx

NEW YORK (GenomeWeb News) - DxS is collaborating with Boehringer Ingelheim to develop a companion diagnostic test kit for the pharmaceutical company's BIBW 2992 (Tovok) drug candidate to identify mutations of the epidermal growth factor receptor in patients with non small cell lung cancer.

Manchester, UK-based DxS said that its EGFR companion diagnostic is a real-time PCR assay that is designed to detect the most common mutations in the EGFR gene. It said that the assay would be ready later this summer for use in Boehringer Ingelheim's phase III study of BIBW 2992.

BIBW 2992 is a tyrosine kinase inhibitor that blocks EGFR/HER2 receptors. In clinical studies, the drug has offered a "marked increase in efficacy" compared to standard treatments in lung cancer patients carrying mutations in the EGFR gene, the firms said.

The partners said that they would work together to make the diagnostic kit globally available. Financial terms and other details of the agreement were not disclosed.

"We are convinced that the collaboration agreement with DxS can expedite our efforts in the field of personalised medicine," Manfred Haehl, senior vice president of medicine for Boehringer Ingelheim, said in a statement.

Filed under

The Scan

Booster Push

New data shows a decline in SARS-CoV-2 vaccine efficacy over time, which the New York Times says Pfizer is using to argue its case for a booster, even as the lower efficacy remains high.

With Help from Mr. Fluffington, PurrhD

Cats could make good study animals for genetic research, the University of Missouri's Leslie Lyons tells the Atlantic.

Man Charged With Threatening to Harm Fauci, Collins

The Hill reports that Thomas Patrick Connally, Jr., was charged with making threats against federal officials.

Nature Papers Present Approach to Find Natural Products, Method to ID Cancer Driver Mutations, More

In Nature this week: combination of cryogenic electron microscopy with genome mining helps uncover natural products, driver mutations in cancer, and more.